Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect.

Carcinogenesis
Liqun HuangBasil Rigas

Abstract

Non-steroidal anti-inflammatory drugs such as sulindac are promising chemoprevention agents against colon cancer, but their weak potency and side effects limit their use for both chemoprevention and chemotherapy. Here, we evaluated the effect of a new sulindac derivative, phospho-sulindac or OXT-922, on the growth of human cancer cell lines and its mechanism of action. OXT-922 inhibited the growth of human cancer cell lines originating from colon, pancreas and breast ~11- to 30-fold more potently than sulindac. This effect was mediated by a strong cytokinetic effect. Compared with control, OXT-922 inhibited cell proliferation by up to 67%, induced apoptosis 4.1-fold over control and blocked the G(1) to S cell cycle phase transition. OXT-922 suppressed the levels of cell cycle regulating proteins, including cyclins D(1) and D(3) and Cyclin-dependent kinases (CDK) 4 and 6. The levels of intracellular reactive oxygen species (ROS), especially those of mitochondrial O₂ⁱ⁻, were markedly elevated (5.5-fold) in response to OXT-922. ROS collapsed the mitochondrial membrane potential and triggered apoptosis, which was largely abrogated by antioxidants. OXT-922 suppressed nuclear factor-kappaB activation and downregulated thioredoxin-1 e...Continue Reading

References

May 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·S T SmileyL B Chen
Nov 1, 1982·The Journal of Cell Biology·J Woodcock-MitchellT T Sun
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·J L VayssiereB Mignotte
May 15, 1993·Archives of Biochemistry and Biophysics·C Giulivi, E Cadenas
Apr 2, 2002·The American Journal of Gastroenterology·Syeda S HusainAndrzej S Tamawski
Apr 5, 2002·The New England Journal of Medicine·Francis M GiardielloStanley R Hamilton
Jun 11, 2003·Progress in Experimental Tumor Research·John A Baron
Sep 25, 2003·The Journal of Biological Chemistry·Naveen BabbarEugene W Gerner
Sep 24, 2004·International Journal of Cancer. Journal International Du Cancer·Sang Hyeok WooChang Hun Rhee
Oct 29, 2004·Nature Reviews. Cancer·Eugene W Gerner, Frank L Meyskens
Nov 3, 2004·Nature Reviews. Molecular Cell Biology·Stefan J Riedl, Yigong Shi
Jul 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takae MinamiKohzoh Imai
Sep 20, 2005·The Journal of Pharmacology and Experimental Therapeutics·Thomas R Hundley, Basil Rigas
Oct 21, 2005·Trends in Biochemical Sciences·Marcos Malumbres, Mariano Barbacid
Nov 12, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jianjun GaoBasil Rigas
Dec 13, 2005·Nature Reviews. Drug Discovery·Bryan T HennessyGordon B Mills
Jul 26, 2006·Expert Opinion on Drug Metabolism & Toxicology·Kathleen M KnightsJohn O Miners
Feb 10, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John P Fruehauf, Frank L Meyskens
Sep 13, 2007·Nature Reviews. Molecular Cell Biology·Benoît D'Autréaux, Michel B Toledano
Apr 3, 2008·Cancer Research·Akila N ViswanathanSusan E Hankinson
Oct 10, 2008·The British Journal of Radiology·A Mukherjee, S G Martin
Feb 6, 2009·Drugs·Marco Lazzaroni, Gabriele Bianchi Porro
Mar 11, 2009·Biochimica Et Biophysica Acta·Dolph L HatfieldVadim N Gladyshev
May 30, 2009·Nature Reviews. Drug Discovery·Dunyaporn TrachoothamPeng Huang
Jun 9, 2009·PloS One·Maria MarchettiDavid Binninger
Jan 22, 2010·International Journal of Cancer. Journal International Du Cancer·Salaheddin M MahmudArmen G Aprikian

❮ Previous
Next ❯

Citations

Feb 26, 2013·Expert Reviews in Molecular Medicine·Shannon L NowotarskiRobert A Casero
Nov 17, 2011·The Journal of Pharmacology and Experimental Therapeutics·Chi C WongBasil Rigas
Dec 19, 2012·International Journal of Molecular Sciences·Amjad M Qandil
Jul 31, 2012·International Journal of Oncology·Ka Wing ChengBasil Rigas
Nov 29, 2013·International Journal of Oncology·Onika T MurrayBasil Rigas
Aug 29, 2013·Oxidative Medicine and Cellular Longevity·Gianluca Farrugia, Rena Balzan
Jul 22, 2014·Biochemical Pharmacology·Gang XieBasil Rigas
Mar 5, 2013·Experimental Gerontology·Ines Sanchez-Roman, Gustavo Barja
Jul 27, 2005·Biochemical and Biophysical Research Communications·Abbas ShakooriToshinari Minamoto
Aug 30, 2016·Ageing Research Reviews·Holly M Brown-Borg, Rochelle Buffenstein
May 7, 2013·Molecular Cancer Therapeutics·Ka Wing ChengBasil Rigas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cell Cycle Pathways

Cell cycle is a complex process regulated by several signal transduction pathways and enzymes. Here is the latest research on regulation of cell cycle and cell cycle pathways.